비교리스트

 카트 문의
시장보고서
상품코드
1405866

당뇨망막병증 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 관리별, 지역별, 부문별 예측(2024-2030년)

Diabetic Retinopathy Market Size, Share & Trends Analysis Report By Type (Proliferative DR, Non-Proliferative DR), By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), By Region, & Segment Forecasts, 2024-2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

당뇨망막병증 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 당뇨망막병증 시장 규모는 2030년까지 137억 7,000만 달러에 달할 것으로 예측되며, 2024-2030년의 CAGR은 6.43%로 확대할 것으로 예측됩니다.

당뇨병 유병률 증가, 노인 인구 증가, 당뇨병으로 인한 실명률 증가는 예측 기간 중 시장 성장을 가속할 것으로 예상되는 주요 요인입니다. 시장 성장은 당뇨병 관리 및 치료에 대한 인식 증가와 신제품 출시로 인해 더욱 촉진될 것입니다. 당뇨망막병증은 망막의 혈관 손상으로 인해 발생하며 대부분의 경우 눈의 흐릿함과 시력 저하로 이어집니다.

고령화, 비만, 불건강한 생활습관으로 인한 당뇨병 유병률 증가가 시장 성장에 기여하고 있습니다. 비만은 당뇨병을 유발하는 주요 요인으로, WHO에 따르면 2021년전 세계 18 세 이상 성인의 약 39%가 과체중이고 13%가 비만이라고합니다. 비만 외에도 당뇨병은 전 세계에서 점점 더 널리 퍼지고 있습니다. 국제당뇨병연맹(IDF)의 추산에 따르면 2021년에는 5억 3700만 명의 성인(20-79세)이 당뇨병을 앓고 있으며, 2020년에는 6억 4200만 명으로 늘어날 것으로 예상했습니다. 2021년에 당뇨병 환자가 가장 많은 지역은 아시아태평양(1억 6,700만 명), 남아시아(8,800만 명), 유럽(5,900만 명)이 될 것이라고 보고했습니다.

노인의 당뇨병은 사망률 증가와 기능 상태의 저하와 직결되기 때문에 노인 인구 증가는 당뇨병 유행의 중요한 촉진제가 되고 있으며, WHO에 따르면 2050년까지 노인 인구의 80%가 중저소득 국가에 거주할 것으로 예상됩니다. 인구의 고령화율은 과거에 비해 상당히 높아 2020년에는 60세 이상 노인의 수가 5세 미만 어린이를 넘어섰고, 2015-2050년까지 세계 인구에서 60세 이상 노인이 차지하는 비중은 12%에서 22%로 거의 두 배로 늘어날 것입니다.

당뇨병성 망막병증 시장 보고서 하이라이트

  • 2023년 유형별 점유율은 비증식성 당뇨망막병증이 가장 큰 비중을 차지할 것으로 보입니다. 당뇨병 병력이 10년 미만인 환자 수가 많기 때문에 이 부문 시장 규모가 커졌습니다.
  • 항VEGF 약물 부문은 2023년 관리별로 가장 큰 점유율을 차지했습니다. 조기 진단 및 경증에서 중등도의 비증식성 DR 치료에서 이러한 약물의 높은 적용 가능성은 부문 성장을 이끄는 주요 요인 중 하나입니다.
  • 아시아태평양 시장은 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이 지역의 많은 인구, 높은 당뇨병 유병률, 노인 인구 증가는 시장을 강화할 가능성이 높습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 당뇨망막병증 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 모시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 촉진요인 분석
    • 시장 억제요인 분석
  • 당뇨망막병증 시장 분석 툴
    • 업계 분석 - Porter의 산업 분석
    • PESTEL 분석

제4장 당뇨망막병증 시장 : 유형 추정·동향 분석

  • 유형 시장 점유율, 2023년·2030년
  • 부문 대시보드
  • 유형별 세계의 당뇨망막병증 시장 전망
  • 이하 시장 규모, 예측 및 동향 분석, 2018-2030년
    • 증식성 당뇨망막병증
    • 비증식성 당뇨망막병증

제5장 당뇨망막병증 시장 : 관리 추정·동향 분석

  • 관리 시장 점유율, 2023년·2030년
  • 부문 대시보드
  • 관리 전망별 세계의 당뇨망막병증 시장
  • 이하 시장 규모, 예측 및 동향 분석, 2018-2030년
    • 항VEGF
    • 스테로이드안내 주사
    • 레이저 수술
    • 초자체 수술

제6장 당뇨망막병증 시장 : 지역 추정·동향 분석

  • 지역 시장 점유율 분석, 2023년·2030년
  • 지역 시장 대시보드
  • 세계의 지역 시장 스냅숏
  • 시장 규모와 예측·동향 분석, 2018-2030년 :
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제7장 경쟁 구도

  • 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
  • 회사/경쟁 분류
  • 벤더 구도
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • Bayer AG
    • ABBVIE INC.
    • Novartis AG
    • Oxurion NV
    • Sirnaomics
    • Alimera Sciences
    • Ampio Pharmaceuticals Inc.
    • BCNPeptides
    • Kowa Company Ltd.
    • Genentech, Inc.
KSA 24.01.25

Diabetic Retinopathy Market Growth & Trends:

The global diabetic retinopathy market size is anticipated to reach USD 13.77 billion by 2030 and is anticipated to expand at a CAGR of 6.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are the major factors anticipated to boost market growth over the forecast period. Growth in the market is further propelled by the increasing awareness about diabetes management & care and new product launches. Diabetic retinopathy is caused by damage to the blood vessels in the retina, which leads to blurred vision and vision loss in most cases.

The increase in prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2021, around 39% of adults aged 18 years and above were overweight, and 13% were obese worldwide. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimated l537 million adults (aged 20 to 79 years) were living with diabetes in 2021, which is expected to rise to 642 million by 2040. The IDF also reports that the prevalence of diabetes is increasing globally, with the highest increases witnessed in low- and middle-income countries. In 2021, the regions with the highest number of adults living with diabetes were the Western Pacific (167 million), South Asia (88 million), and Europe (59 million).

The rising geriatric population is a significant driver of the diabetes epidemic, as diabetes in older people is directly linked with higher mortality and reduced functional status. According to WHO, 80% of older people are expected to live in low- and middle-income nations by 2050. The population is aging at a considerably higher rate than in the past. In 2020, the number of persons aged 60 years and more will outnumber children under the age of 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years will nearly double, from 12% to 22%.

Diabetic Retinopathy Market Report Highlights:

  • Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2023. The presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.
  • Anti-VEGF segment accounted for the largest share, by management, in 2023. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.
  • The Asia Pacific market is expected to grow with the highest CAGR over the forecast period. Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Management
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Management outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of diabetes
      • 3.2.1.2. Growing geriatric population
      • 3.2.1.3. Increasing prevalence of blindness due to diabetes
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of accurate diagnosis
      • 3.2.2.2. Adverse effect on treatment
  • 3.3. Diabetic Retinopathy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Diabetic Retinopathy Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Proliferative Diabetic Retinopathy
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-proliferative Diabetic Retinopathy
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis

  • 5.1. Management Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Diabetic Retinopathy Market by Management Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Anti-VEGF
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Intraocular Steroid Injection
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laser Surgery
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Vitrectomy
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Bayer AG
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. ABBVIE INC.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Novartis AG
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Oxurion NV
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Sirnaomics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Alimera Sciences
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Ampio Pharmaceuticals Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. BCNPeptides
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Kowa Company Ltd.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Genentech, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제